Calder Biosciences

Executive Summary

Calder Biosciences is a private, early-stage biotechnology company leveraging its proprietary 3D-Vaxlock™ platform to engineer conformationally stabilized, prefusion viral proteins for next-generation subunit vaccines. Founded in 2018 and based in New York, the company initially targets respiratory viruses such as RSV and influenza, aiming to overcome limitations of current vaccines in terms of durability, thermostability, and global distribution. The platform's ability to lock viral proteins in their native prefusion state has the potential to elicit more potent and broad immune responses, addressing a critical need in infectious disease prevention. Though still in preclinical development, Calder's approach holds promise for improving vaccine efficacy and accessibility. However, as a private company with no disclosed funding or clinical-stage pipeline, its near-term trajectory relies on advancing lead candidates into human trials and securing strategic partnerships to support manufacturing and commercialization. The competitive landscape in RSV and influenza vaccines is intense, with multiple approved and pipeline candidates. Success will depend on demonstrating superior immunogenicity and safety profiles in early clinical studies, as well as establishing scalable production processes for its stabilized proteins.

Upcoming Catalysts (preview)

• Q3 2026Initiation of Phase 1 trial for RSV vaccine candidate60% success
• Q4 2026Preclinical data readout for influenza vaccine candidate50% success
• Q3 2026Announcement of strategic partnership or funding round70% success